Generic Riociguat Launched for Rare Lung Conditions
Healthcare providers and pharmacies now have access to a lower-cost generic alternative to Adempas.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Do you believe the introduction of generic drug versions effectively reduces your long-term healthcare costs?
Zydus Lifesciences and MSN Laboratories have launched the first generic versions of riociguat in the United States following FDA approval. The medication is used to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Why it matters
The introduction of generic riociguat provides a lower-cost alternative for patients requiring long-term treatment for rare lung conditions. This market entry challenges the incumbent brand, Adempas, which generated approximately $850 million in global sales during 2025.
The generic riociguat is available in five strengths—0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg—following FDA approval. This launch follows a 2025 fiscal year in which Bayer reported $850 million in global sales for the reference product.
The players
Zydus Lifesciences
An Indian multinational pharmaceutical company that develops and manufactures generic drugs for global markets.
MSN Laboratories
A pharmaceutical manufacturer focused on active pharmaceutical ingredients and finished dosage generic products.
Bayer
A multinational life sciences company that produces the brand-name pulmonary treatment Adempas.
The details
MSN Laboratories manufactured the medication, while Zydus Lifesciences is managing the U.S. commercial platform. The companies executed a simultaneous launch across all five approved dosage strengths. This operational deployment structure allows for immediate coverage across the full spectrum of patient prescriptions.
Timeline
2025: Bayer recorded $850 million in global Adempas sales.
October 5, 2026: Zydus Lifesciences shares closed on the NSE.
Market Landscape
This market entry follows the established pattern of competition governed by the FDA generic drug approval pathway. It represents a significant shift for a therapy segment previously dominated by a single branded product.
Healthcare providers should evaluate how this generic availability impacts cost-sharing and patient access for long-term treatment plans. Pharmacists and clinic managers should update inventory and procurement lists to account for the availability of the new 0.5 mg through 2.5 mg strengths.
The takeaway
The arrival of generic riociguat marks a pivotal cost-saving shift for patients managing complex pulmonary conditions. Operators should monitor potential shifts in wholesale pricing and insurance coverage as generic alternatives gain traction in the market.
Further reading
For broader trends in pharmaceutical market shifts, explore the Healthcare section.
Live Poll
Do you believe the introduction of generic drug versions effectively reduces your long-term healthcare costs?
